Healthcare Professional

The information in this section is intended exclusively for HCPs in Europe.

By checking the box you confirm you are a licensed HCP and understand that cenobamate is not approved in Europe.

Take me back to Home

Welcome to Arvelle’s Medical Information Services

Our mission is to provide you with accurate, timely, tailor-based, balanced scientific information to answer your medical information requests. You can also use this webpage to report any adverse event or product complaint.

To view our Early Access Programme Policy, please click on the link below

Early Access Programme Policy

To report an adverse event or a product quality complaint, or for medical information, please call:

France +33 (0)1 8824 7098
Germany +49 (0)89 1208 5269
Italy +39 (0)8 0019 4695
Spain +34 (0)9 0903 0223
Sweden +46 (0)8 4468 8842
United Kingdom +44 (0)20 7458 4107
International Free Number 00 800 0825 0827

You can submit medical information requests via email, using medinfo@arvelletx.com

BECAUSE YOU KEEP GOING, WE'LL KEEP GOING.

Despite medication, approximately 40% of patients with epilepsy do not achieve seizure freedom after two different anti-seizure medications.1, 2, 3

Nevertheless, they persevere.

Watch video

60%

Focal-onset seizures (FOS) account for over 60% of all epilepsy cases.4

FOS are more often uncontrolled compared to patients with generalised seizures.5 Even with significant therapy advancements, overall treatment outcomes have not significantly improved in the past 20 years.1, 6 Many patients with drug-resistant FOS do not reach seizure freedom, despite trying two or more ASMs.1

Is it any wonder that treatment goals are often reassessed?

The impact of uncontrolled seizures on patient health is high.

Compared to patients who are seizure free, patients with uncontrolled seizures are:7, 8

  • have a higher risk of death**
  • 6x more likely to have depression.*
  • 3x more likely to have poor health.*

* Experiencing at least one seizure in the past five years compared with those who were seizure free for five years.7
** Incidence rate ratio 9.3–13.4.8

Uncontrolled seizures have additional psychosocial implications.

Patients with uncontrolled seizures are:7

  • 2x as likely to experience stigma in their daily lives.
  • 4.5x more likely to be prevented from driving.
  • 3x more likely to have restrictions in employment.
  • 2x as likely to have limited education.

Reducing seizure frequency brings many benefits to patients, but the outcome that has the greatest impact is achieving seizure freedom.9, 10

In clinical trials, a 50% reduction in seizure frequency is an important endpoint to evaluate efficacy.11 In clinical practice, it is seizure freedom that brings hope back to patients and allows them to have a better life.9

Assess your treatment goals. As your patients persevere, so do you.

  • What is the path to achieving seizure freedom?*

  • What is the most effective way to reduce seizure frequency?

  • How can we reduce seizure severity?**

  • How can we minimise side effects?

* Defined as being free from seizures for 12 months or longer.1
** Defined as seizure type.

The treatment goal in epilepsy therapy should be the reduction of seizure frequency and severity and, eventually, achieving seizure freedom.9, 10, 11

There is a need for more effective treatments for patients with drug-resistant focal-onset seizures.

Arvelle recognises this, and we are focused on bringing innovative treatments to patients living with CNS disorders.

Discover more about Arvelle
Close
    1. Chen Z, et al. JAMA Neurol. 2018;75(3):279–286.
    2. Kwan P and Brodie MJ. N Engl J Med. 2000;342(5):314–319.
    3. Kwan P, et al. Epilepsia. 2010;51(6):1069–1077.
    4. Schmitz B, et al. Epilepsia. 2010;51(11):2231–2240.
    5. Cockerell OC, et al. Epilepsia. 1997;38(1):31–46.
    6. Costa J, et al. Epilepsia. 2011;52(7):1280–1291.
    7. Josephson CB, et al. Epilepsia. 2017;58(5):764–771.
    8. Thurman DJ, et al., Epilepsia. 2017;58(1):17–26.
    9. Choi H, et al. Epilepsia. 2014;55(8):1205–1212.
    10. Poochikian-Sarkissian S, et al. Can. J. Neurol. Sci. 2008; 35(3): 280–286.
    11. CHMP, EMA. Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders. July 2018. CHMP/EWP/566/98 Rev.3.